Overview

• Biopharmaceutical firm's Q4 revenue decreased significantly compared to last year

• Net loss for Q4 narrowed to $15.5 mln from $33.8 mln last year

• Company strengthened financial position with over $100 mln in additional cash

Outlook

• Lexicon expects SONATA-HCM study enrollment to complete by mid-2026

• Company plans NDA resubmission for ZYNQUISTA in 2026

• Lexicon supports Viatris in regulatory filings for sotagliflozin in 2026

Result Drivers

• EXPENSE REDUCTION - Decreased R&D and SG&A expenses contributed to a narrowed net loss for Q4 2025

Company press release: ID:nGNX5DRRX6

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Product Revenue		$1.06 mln
Q4 EPS		-$0.04
Q4 Net Income		-$15.53 mln
Q4 Basic EPS		-$0.04
Q4 Operating Expenses		$20.27 mln
Q4 Operating Income		-$14.78 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $3.05, about 87.1% above its March 4 closing price of $1.63

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.